Rybrevant双靶风暴来袭:强生重塑难治性结直肠癌治疗天花板,51% ORR+11.3月肝转移PFS,EGFR/MET双锁+免疫杀伤直击耐药痛点

医道社创新药新...
Jan 13

医道社:传承和发展民间中医来源:海外网站 作者:医道社整理版权归原作者所有,如有违规、侵权请联系我们删除!关注不迷路,更多创新药前沿资讯各位临床医生和药品研发同行,大家好!我是你们的创新药专业博主老汤,平时总爱深挖那些能真正改变临床实践的突破。今天咱们聊聊强生Rybrevant(阿米伐他单抗,amivantamab-vmjw)在转移性结直肠癌(mCRC)领域的最新进展。这款原本在肺癌战场上大放异彩...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10